FDA nominee faces intense questioning on mifepristone safety and vaccine advisory meeting cancellation, raising concerns over data-driven policy decisions.
FDA nominee faces intense questioning on mifepristone safety and vaccine advisory meeting cancellation, raising concerns over data-driven policy decisions.